Sep 17 |
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
|
Sep 5 |
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
|
Sep 4 |
Athira plunges as Alzheimer’s trial setback leads to downgrades
|
Sep 4 |
Alzheimer’s Trial Failure Sends Athira Stock Down 75%
|
Sep 4 |
Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial
|
Sep 4 |
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
|
Sep 4 |
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
|
Sep 3 |
Athira stock craters 72% on failed study for Alzheimer's drug
|
Sep 3 |
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
|
Aug 23 |
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
|